Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
525 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06667154 | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | recruiting | Phase 2 | 33 | Aline Fusco Fares, MDOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05558007 | Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients | recruiting | Phase 2 | 72 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Oct 22, 2024 | clinicaltrials |
| NCT02743221 | A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy(TASCO1) | completed | Phase 2 | 154 | Institut de Recherches Internationales ServierOTHER | 12 | Aug 20, 2024 | clinicaltrials |
| NCT06537843 | Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia(VenCM) | recruiting | Phase 2 | 100 | Hospital Municipal São JoséOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma(PANORAMA_3) | completed | Phase 2 | 248 | pharmaand GmbHINDUSTRY | 22 | Jul 12, 2024 | clinicaltrials |
| NCT05215470 | CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy | active not recruiting | Phase 2 | 100 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06472388 | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors(EVENET) | recruiting | Phase 2 | 100 | AC Camargo Cancer CenterOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 | clinicaltrials |
| NCT03870399 | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression(HORMONET) | completed | Phase 2 | 23 | AC Camargo Cancer CenterOTHER | 2 | May 6, 2024 | clinicaltrials |
| NCT01626664 | KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) | completed | Phase 2 | 71 | Kyowa Kirin, Inc.INDUSTRY | 6 | Apr 25, 2024 | clinicaltrials |
| NCT03700099 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03148795 | A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 128 | PfizerINDUSTRY | 14 | Apr 5, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT05850637 | Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer | completed | Phase 2 | 60 | Prevent Senior InstituteOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04224740 | Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer(HERCULES) | completed | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03936270 | Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | completed | Phase 2 | 43 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity(INSPIRE) | completed | Phase 2 | 105 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 4 | Jan 30, 2024 | clinicaltrials |
| NCT03840902 | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 153 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Jan 16, 2024 | clinicaltrials |
| NCT05492123 | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | recruiting | Phase 2 | 112 | Hospital Israelita Albert EinsteinOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03674112 | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer(PHranceSCa) | completed | Phase 2 | 160 | Hoffmann-La RocheINDUSTRY | 17 | Jan 2, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT04271384 | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | completed | Phase 2 | 25 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT01514864 | Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | terminated | Phase 2 | 19 | Bristol-Myers SquibbINDUSTRY | 7 | Dec 19, 2023 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | terminated | Phase 2 / Phase 3 | 309 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Nov 14, 2023 | clinicaltrials |
| NCT01750281 | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.(SELECT-2) | completed | Phase 2 | 212 | AstraZenecaINDUSTRY | 8 | Oct 24, 2023 | clinicaltrials |
| NCT04246489 | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | completed | Phase 2 | 146 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | Oct 23, 2023 | clinicaltrials |
| NCT04267315 | Trigger Point Injections for Post-Mastectomy Pain Syndrome | unknown | Phase 2 | 72 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05081674 | Brazilian Lung Immunotherapy Study(BLISS) | completed | Phase 2 | 154 | Hospital Israelita Albert EinsteinOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05800834 | Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds(MorphineGEL) | unknown | Phase 2 | 106 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05840835 | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors(IMMINENT-01) | unknown | Phase 1 / Phase 2 | 60 | Immix Biopharma, Inc.INDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05900973 | A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer | unknown | Phase 2 | 19 | D'Or Institute for Research and EducationOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00245154 | Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 296 | NCIC Clinical Trials GroupNETWORK | 6 | Aug 4, 2023 | clinicaltrials |
| NCT03789149 | Focal Intraoperative Radiotherapy of Brain Metastases | terminated | Phase 2 | 10 | AC Camargo Cancer CenterOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03283488 | Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. | completed | Phase 2 | 52 | University of Sao PauloOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT02211131 | Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma | completed | Phase 2 | 150 | AmgenINDUSTRY | 9 | Jun 5, 2023 | clinicaltrials |
| NCT03519256 | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder(CheckMate 9UT) | terminated | Phase 2 | 142 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 1, 2023 | clinicaltrials |
| NCT01698918 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer(BOLERO-4) | completed | Phase 2 | 202 | Novartis PharmaceuticalsINDUSTRY | 13 | May 3, 2023 | clinicaltrials |
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
| NCT05541146 | Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | unknown | Phase 1 / Phase 2 | 115 | Kartos Therapeutics, Inc.INDUSTRY | 10 | Mar 2, 2023 | clinicaltrials |
| NCT03870607 | Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT)(BISQUIT) | unknown | Phase 2 | 75 | AC Camargo Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT04168931 | Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC(GASTHER2) | terminated | Phase 2 | 5 | AC Camargo Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials